Aziyo Biologics announces publication of a CanGaroo case study

Aziyo Biologics announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs. The report, titled “Rehabilitation of an Existing Device Implant Pocket Using a Biologic Extracellular Matrix Envelope,” was published in the peer-reviewed journal Heart Rhythm Case Reports. The results suggest a biological envelope may mitigate the risks and procedural difficulty associated with reusing fibrotic implant pockets, which could facilitate future reoperations and decrease post-operative complications. This case study builds upon interim results from the HEAL Study indicating that CanGaroo can significantly reduce fibrous lead entrapment and decrease procedural difficulty when used during initial device implantation. CanGaroo is the only biological envelope available for use with implantable electronic devices. “This case study builds upon the interim HEAL Study data presented earlier this year at Heart Rhythm 2023,” said Dr. Michelle LeRoux Williams, Chief Scientific Officer of Aziyo. “These results provide an opportunity to evaluate the use of CanGaroo within a reoperative pocket. CanGaroo has proven to show superior tissue remodeling properties and can provide a solution for patients and their physicians seeking to avoid complications associated with reoperations.”